drugset / Trial / NCT05528679
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
Timeline
- Start
- 2022-09
- Primary completion
- 2023-09
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 610 | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | 610 | Monoclonal antibody | 300 mg | Subcutaneous |